More on Comparison of HMG-CoA Reductase Inhibitors

Abstract

Get full access to this article

View all access options for this article.

References

Shaughnessy

Slawson

. Comment: comparison of HMG-CoA reductase inhibitors (letter). Ann Pharmacother 1995; 29: 1304.

Hsu

Spinler

Johnson

. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995; 29: 743–59.

Shepherd

Cobbe

Ford

Isles

Lorimer

MacFarlane

. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.

Furberg

Pitt

Byington

Park

J-S

McGovern

. Reduction in coronary events during treatment with pravastatin. Am J Cardiol 1995; 76: 60C–3C.

Pfeffer

Sacks

Moye

Brown

Rouleau

Hartley

. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. Am J Cardiol 1995; 76: 98C–106C.

Tonkin

. Management of the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 107C–12C.

Jones

Gotto

. Extending the benefit of lipid-regulating therapy to primary prevention. Am J Cardiol 1995; 76: 118C–21C.